Skip to main content
Fig. 7 | Cancer Cell International

Fig. 7

From: STK25 enhances hepatocellular carcinoma progression through the STRN/AMPK/ACC1 pathway

Fig. 7Fig. 7Fig. 7

STK25 knockdown inhibits tumor growth and lipid metabolism pathway in a xenograft mouse model. a Weight of mice. b Representative images of tumor-bearing mice implanted with HepG2-shControl or HepG2-shSTK25 cells (Left). Tumor masses were harvested from the corresponding xenografts on Day 28 (Right). c Tumor weights. d Representative images of Subcutaneous tumor from control and sh-STK25 groups immunostained with Ki67 (200×), the thick yellow arrow indicated Ki67. e Quantification of Ki67 + cells. (f) Representative IHC staining images (200×) of STK25 and STRN expression. g, h Representative images of subcutaneous tumor from control and sh-STK25 groups immunostained with STK25 (red), ACC1/ACLY (green) and DAPI (blue). The depletion of STK25 was accompanied by the decrease of ACC1 and ACLY. (i) Quantification of immunofluorescence for STK25, ACC1, ACLY. j Representative western blots of STK25 expression and genes related to lipid metabolism. k Quantification of western blot for STK25 and genes related to lipid metabolism fold change in sh-STK25 compared with that in control group. l Representative IHC staining images (200×)of EMT-related markers E-cadherin and N-cadherin in subcutaneous tumor. m, n Representative western blots and quantification of EMT-related markers in subcutaneous tumor. CON, control. Data are expressed as mean ± SD. *, p < 0.05. **, p < 0.01. ***, p < 0.001. Scale bars, 50 μm

Back to article page